What is Valencia Technologies?
Valencia Technologies Corporation operates at the intersection of bioelectronics and clinical medicine, specializing in the development of advanced peripheral neurostimulation solutions. The company's flagship innovation, the eCoin, is a nickel-sized implantable device designed to treat overactive bladder symptoms. By utilizing a streamlined, 20-minute office-based procedure under local anesthesia, Valencia aims to disrupt traditional treatment paradigms that often rely on more invasive surgical methods or long-term pharmaceutical regimens. Currently, the company is focused on executing its pivotal clinical trial, a critical step required to support a pre-market approval application and validate the efficacy of its technology for widespread clinical adoption.
The firm's operational strategy centers on reducing the barrier to entry for neurostimulation therapy. By prioritizing ease of implantation and patient comfort, Valencia Technologies is positioning itself as a leader in the neuromodulation space, targeting a significant patient demographic that remains underserved by existing therapeutic options.
How much funding has Valencia Technologies raised?
Valencia Technologies has raised a total of $35.1M across 2 funding rounds:
Debt
$150K
Other Financing Round
$35M
Debt (2020): $150K with participation from PPP
Other Financing Round (2025): $35M led by Brooks Advisory Group
Key Investors in Valencia Technologies
Brooks Advisory Group
Brooks Advisory Group is an investment banking firm based in North Carolina that provides strategic financial guidance and capital market support to emerging growth companies.
PPP
Public-Private Partnership
What's next for Valencia Technologies?
With the recent capital injection, Valencia Technologies is well-positioned to accelerate its regulatory roadmap and scale its clinical trial infrastructure. The primary objective remains the successful completion of the pivotal trial for the eCoin device, which serves as the cornerstone for future commercialization efforts. As the company moves toward potential pre-market approval, management will likely focus on refining manufacturing processes and establishing the necessary distribution channels to support a national rollout. The strategic backing provided by its investment partners will be instrumental in navigating the complex regulatory landscape of the medical technology industry, ensuring that the company can effectively transition from an investigational stage to a commercial-ready enterprise capable of delivering long-term value to both patients and stakeholders.
See full Valencia Technologies company page
